# Srini Akkaraju

> Srini Akkaraju is a Series A investor at Samsara BioCapital backing Biotechnology and Biopharma. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital)
- Total investments: 6
- Last investment: Dec 2025
- Lead investor: 67%
- Last updated: Aug 2026

Srini Akkaraju is a Series A investor at Samsara BioCapital focused on Biotechnology and Biopharma. Srini Akkaraju

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 83% |
| Biopharma | 4 | 67% |
| Medical | 3 | 50% |
| Life Science | 2 | 33% |
| Chemical | 1 | 17% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 50% |
| Series B | 1 | 17% |
| Series C | 1 | 17% |
| Post-IPO Equity | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 67% |
| United Kingdom | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Psivant Therapeutics | Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services. | $47.5M | Series A | Dec 10, 2025 |  |
| Mineralys Therapeutics | Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from MitsubishiTanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. | $118M | Series B | Jun 08, 2022 |  |
| Mineralys Therapeutics | Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from MitsubishiTanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension. | $40M | Series A | Apr 06, 2021 |  |
| EGenesis | EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $125M | Series C | Mar 02, 2021 |  |
| MiroBio | MiroBio's platform is based on ground-breaking research by their scientific founders at the University of Oxford delineating how immune cells communicate and how they are activated. These insights have enabled MiroBio to create antibodies that can leverage natural signalling mechanisms to restore immune system balance and control. |  | Series A | Oct 07, 2019 |  |
| Lite Strategy | MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients inmultiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing. | $27.5M | Post-IPO Equity | Nov 05, 2012 |  |

6 of 6 investments shown.

## Co-investors
- [Catalys Pacific](https://shizune.co/investors/profile/catalys-pacific) — VC Fund, 4 deals together
- [HBM Healthcare Investments](https://shizune.co/investors/profile/hbm-healthcare-investments-ag) — VC Fund, 3 deals together
- [Adams Street Partners](https://shizune.co/investors/profile/adams-street-partners) — VC Fund, 2 deals together
- [HBM Partners](https://shizune.co/investors/profile/hbm-partners) — VC Fund, 2 deals together
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 2 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 2 deals together

## About Samsara BioCapital

VC Fund · Palo Alto, United States

Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotesbiotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.

5 contacts available at Samsara BioCapital.

| Name | Title | Profile |
| --- | --- | --- |
| Abraham Bassan | Partner | https://shizune.co/investors/profile/abraham-bassan |
| Michael Dybbs | Partner | https://shizune.co/investors/profile/mike-dybbs |
| Christian Richard | Head of Public Research | https://shizune.co/investors/profile/christian-m-richard |
| Marcos Milla | Venture Partner | https://shizune.co/investors/profile/marcos-milla |
| Srini Akkaraju | Founder | https://shizune.co/investors/profile/srini-akkaraju |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Srini Akkaraju invest in?

Srini Akkaraju invests primarily in Biotechnology, Biopharma and Medical startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Srini Akkaraju last invest?

The most recent investment recorded for Srini Akkaraju closed in Dec 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co